High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients

被引:52
|
作者
Shafer, RW
Hertogs, K
Zolopa, AR
Warford, A
Bloor, S
Betts, BJ
Merigan, TC
Harrigan, R
Larder, BA
机构
[1] Stanford Univ, Med Ctr, Div Infect Dis, Stanford, CA 94305 USA
[2] Stanford Univ, Med Ctr, AIDS Res Ctr, Stanford, CA 94305 USA
[3] Stanford Univ Hosp, Diagnost Virol Lab, Stanford, CA 94305 USA
[4] Stanford Univ Hosp, Dept Biostat, Stanford, CA 94305 USA
[5] VIRCO Belgium, Cent Virol Lab, Mechelen, Belgium
[6] VIRCO UK, Cambridge CB4 4GH, England
关键词
D O I
10.1128/JCM.39.4.1522-1529.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We assessed the reproducibility of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and protease sequencing using cryopreserved plasma aliquots obtained from 36 heavily treated HIV-1-infected individuals in two laboratories using: dideoxynucleotide sequencing. The rates of complete sequence concordance between the two laboratories were 99.1% for the protease sequence and 99.0% for the RT sequence. Approximately 90% of the discordances were partial, defined as one laboratory detecting a mixture and the second laboratory detecting only one of the mixture's components. Only 0.1% of the nucleotides were completely discordant between the two laboratories, and these were significantly more likely to occur in plasma samples with lower plasma HIV-I RNA levels, Nucleotide mixtures were detected at approximately 1% of the nucleotide positions, and in every case in which one laboratory detected a mixture, the second laboratory either detected the same mixture or detected one of the mixture's components. The high rate of concordance in detecting mixtures and the fact that most discordances between the two laboratories were partial suggest that most discordances were caused by variation in sampling of the HIV-1 quasispecies by PCR rather than by technical errors in the sequencing process itself.
引用
收藏
页码:1522 / 1529
页数:8
相关论文
共 50 条
  • [21] Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: Clinical impact and molecular mechanisms
    Winters, MA
    Merigan, TC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) : 2575 - 2582
  • [22] Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes
    Snoeck, J
    Riva, C
    Steegen, K
    Schrooten, Y
    Maes, B
    Vergne, L
    Van Laethem, K
    Peeters, M
    Vandamme, AM
    JOURNAL OF VIROLOGICAL METHODS, 2005, 128 (1-2) : 47 - 53
  • [23] A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
    Hertogs, K
    de Béthune, MP
    Miller, V
    Ivens, T
    Schel, P
    Van Cauwenberge, A
    Van den Eynde, C
    Van Gerwen, V
    Azijn, H
    Van Houtte, M
    Peeters, F
    Staszewski, S
    Conant, M
    Bloor, S
    Kemp, S
    Larder, B
    Pauwels, R
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (02) : 269 - 276
  • [24] Mutations in human immunodeficiency virus type 1 reverse transcriptase that make it sensitive to degradation by the viral protease in virions are selected against in patients
    Dunn, Linda L.
    Boyer, Paul L.
    McWilliams, Mary Jane
    Smith, Steven J.
    Hughes, Stephen H.
    VIROLOGY, 2015, 484 : 127 - 135
  • [25] Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target
    Srivastava, S.
    Sluis-Cremer, N.
    Tachedjian, G.
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (15) : 1879 - 1894
  • [26] Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
    de la Carrière, LC
    Paulous, S
    Clavel, F
    Mammano, F
    JOURNAL OF VIROLOGY, 1999, 73 (04) : 3455 - 3459
  • [27] Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations
    Monno, L
    Appice, A
    Cavaliere, R
    Scarabaggio, T
    Angarano, G
    JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02): : 568 - 570
  • [28] Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer
    Wapling, J
    Moore, KL
    Sonza, S
    Mak, J
    Tachedjian, G
    JOURNAL OF VIROLOGY, 2005, 79 (16) : 10247 - 10257
  • [29] Differential Evolution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Genes Between HAART-Failing and Naive-Treated Individuals
    Varella, Rafael B.
    Schrago, Carlos G.
    Zalis, Mariano G.
    CURRENT HIV RESEARCH, 2009, 7 (06) : 601 - 605
  • [30] ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase
    Naeger, LK
    Margot, NA
    Miller, MD
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (07) : 2179 - 2184